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Abstract
 
B cell entry to lymph nodes and Peyer’s patches depends on chemokine receptor signaling, but
the principal chemokine involved has not been defined. Here we show that the homing of
CXCR4
 

 
/
 
 
 
B cells is suppressed in CCL19 (ELC)- and CCL21 (SLC)-deficient paucity of
lymph node T cells mice, but not in wild-type mice. We also find that CXCR4 can contribute
to T cell homing. Using intravital microscopy, we find that B cell adhesion to high endothelial
venules (HEVs) is disrupted when CCR7 and CXCR4 are predesensitized. In Peyer’s patches,
B cell entry is dependent on CXCR5 in addition to CCR7/CXCR4. CXCL12 (SDF1) is dis-
played broadly on HEVs, whereas CXCL13 (BLC) is found selectively on Peyer’s patch follic-
ular HEVs. These findings establish the principal chemokine and chemokine receptor require-
ments for B cell entry to lymph nodes and Peyer’s patches.
Key words: chemokine • high endothelial venule • adhesion • lymphoid organ • B cell
 
Introduction
 
Lymphocyte passage from blood into lymph nodes and
Peyer’s patches is a multistep process (1, 2). First, lympho-
cytes are captured and roll on high endothelial venules
(HEVs)
 
*
 
 via adhesive interaction between the selectins on
lymphocytes and their counterreceptors on HEVs. This se-
lectin-supported rolling is followed by triggering events
signaled through Gi protein–coupled receptors that induce
integrin-dependent firm adhesion. Once firm adhesion has
been achieved, the lymphocytes proceed through an addi-
tional series of steps that lead to migration across the endo-
thelium and movement into the lymphoid tissue.
The critical involvement of Gi protein–coupled signal-
ing in T and B lymphocyte homing was established
through the discovery of a strong inhibitory effect of per-
tussis toxin on lymphocyte homing (3–6). This finding im-
plicated chemokines and chemokine receptors in T and B
lymphocyte entry to lymphoid tissues, as all chemokine re-
ceptors couple to pertussis toxin–sensitive G proteins. Cir-
culating B and T lymphocytes express multiple chemokine
receptors including CCR7, the receptor for CCL19 (ELC)
and CCL21 (SLC), CXCR4, the receptor for CXCL12
(SDF1), and in the case of B cells, CXCR5, the receptor
for CXCL13 (BLC). CCL21 was found to be expressed at
high levels by HEVs (7) and more recently, CCL19 has
been observed on HEVs (8). In flow chamber studies, both
CCL21 and CCL19 could promote firm adhesion of roll-
ing lymphocytes (9, 10). A critical role for CCR7 and
CCL19/CCL21 in T cell homing has been established
from genetic studies. Mice homozygous for a spontaneous
mutation, paucity of lymph node T cells (
 
plt
 
), lack the
CCL19 gene and the gene for lymphoid tissue, CCL21
(CCL21-ser; references 11–14). Transfer studies have es-
tablished that 
 
plt
 
/
 
plt
 
 mice are poorly able to support the
 
The online version of this article contains supplemental material.
Address correspondence to Jason G. Cyster, Department of Microbiol-
ogy and Immunology, University of California San Francisco, 513 Par-
nassus Avenue, San Francisco, CA 94143. Phone: 415-502-6427; Fax:
415-502-8424; E-mail: cyster@itsa.ucsf.edu
 
*
 
Abbreviations used in this paper:
 
 AP, alkaline phosphatase; B6, C57BL/6
mice; CFSE, 5- and 6-carboxyfluorescein diacetate succinimidyl ester;
FBS, fetal bovine serum; HEV, high endothelial venule; HRP, horserad-
ish peroxidase; ICAM1, intercellular adhesion molecule 1; MAdCAM,
mucosal addressin cell adhesion molecule; plt, paucity of lymph node T
 
cells; PNAd, peripheral node addressin; TRITC, tetramethylrhodamine-5-
and 6-isothiocyanate.
 66
 
Chemokines Required for B Cell Homing
 
firm adhesion of T cells to HEVs (15, 16). A second
CCL21 gene that differs from CCL21-ser in a single
codon, CCL21-leu, is retained in 
 
plt
 
/
 
plt
 
 mice and ex-
pressed by lymphatic vessels outside lymphoid tissues (12,
14). Consistent with the findings in 
 
plt/plt
 
 mice, T cells
lacking CCR7 are markedly suppressed in their ability to
enter wild-type lymph nodes and Peyer’s patches (17).
Therefore, CCL19/CCL21 and the receptor CCR7 play
an important role in the multistep process of T lymphocyte
entry to lymph nodes and Peyer’s patches.
Despite the significant advances in our understanding of
the chemokine requirements for T cell homing across
HEVs, the chemokine(s) involved in B cell homing are not
well established. Although transferred CCR7-deficient B
cells showed diminished accumulation in lymph nodes and
Peyer’s patches compared with wild-type B cells, no such
effect was seen on B cell homing to the lymph nodes of 
 
plt
 
mice (17, 18). Furthermore, the transition from rolling to
firm adhesion of B cells in Peyer’s patch HEVs was not af-
fected by using 
 
plt
 
 mice as recipients, nor by predesensitiz-
ing CCR7 on donor B cells (16). Interestingly, CCR7 and
its ligands also do not fully account for T cell homing to
lymph nodes and Peyer’s patches, as a small number of
CCR7-deficient T cells were observed to enter these tis-
sues in short-term transfer experiments (17).
No chemokines other than CCL19/CCL21 have been
directly established to function in lymphocyte homing to
lymph nodes and Peyer’s patches. CXCL12 and its recep-
tor, CXCR4, function in B cell development by promot-
ing the retention of B cell precursors in bone marrow
(19 and references therein). However, in the periphery,
CXCR4-deficient lymphocytes were found to efficiently
repopulate secondary lymphoid organs (19). In addition, al-
though CXCL12 promoted lymphocyte adhesion in flow
chamber studies (9), the desensitization of CXCR4 did not
affect the transition from rolling to sticking of B or T cells
in Peyer’s patch HEVs (16). Studies of CXCL13 and
CXCR5 have shown that naive B cells and a subset of acti-
vated and memory T cells localize in a CXCR5-dependent
manner in the lymphoid follicles where CXCL13 is pro-
duced (20, 21). However, so far there has not been any ev-
idence that these molecules take part in the mechanism of
lymphocyte entry into lymphoid organs.
Here we find that the combined blockade of the chemo-
kine signals through CXCR4 and CCR7 strongly dimin-
ishes the homing of B cells to lymph nodes and Peyer’s
patches. CXCL12 mRNA was found in cells adjacent to
HEVs, and protein could be detected on the HEV lumen.
Intravital microscopy with chemokine-desensitized cells re-
vealed that CXCR4 and CCR7 are used for the transition
of B cells from rolling to firm adhesion on HEVs. Further-
more, we show that CXCL13 and CXCR5 play an impor-
tant role in B cell homing to Peyer’s patches.
 
Materials and Methods
 
Mice and Fetal Liver Chimeras.
 
C57BL/6 (B6) mice were pur-
chased from Jackson ImmunoResearch Laboratories, and B6-
 
Ly5
 
a
 
, BALB/c, and B6 mice with jugular vein catheters were
purchased from Charles River Laboratories. Mice with 
 
plt
 
 muta-
tion on BALB/c background (BALB/c-
 
plt
 
/
 
plt
 
; reference 18)
were crossed with B6 six times and intercrossed to generate
 
plt
 
/
 
plt
 
 homozygous mice (termed B6-plt/plt). CXCR5
 

 
/
 

 
,
CXCR5
 

 
/
 

 
, and BLC
 

 
/
 
 
 
mice were on a mixed B6 and 129
background and were screened as previously described (20, 21).
To make CXCR4
 

 
/
 
 
 
or CXCR4
 

 
/
 
 
 
chimeras, B6-Ly5
 
a 
 
mice
that had been lethally irradiated were reconstituted with
CXCR4
 

 
/
 
 
 
or CXCR4
 

 
/
 
 
 
fetal liver cells as previously de-
scribed (22). The CXCR4 mutation was generated on the 129
background and had been backcrossed six generations to B6. To
provide CCR7
 

 
/
 
 
 
cells for adoptive transfer, bone marrow from
CCR7
 

 
/
 
 
 
mice on a mixed B6 and 129 background (17), and
that in some cases also carried Ig
 
HEL
 
-transgenes (23), was used to
reconstitute lethally irradiated B6 mice, as previously described
(24). After 5–6 wk of reconstitution, spleen cells from the
CCR7
 

 
/
 
 
 
chimeric animals were used for adoptive transfers. No
differences were observed in the homing of non- or Ig-transgenic
CCR7
 

 
/
 
 
 
B cells.
 
Adoptive Transfer.
 
Splenocytes from CXCR4
 

 
/
 
 
 
or CXCR4
 

 
/
 

 
chimeras, and CXCR5
 

 
/
 

 
, CXCR5
 

 
/
 

 
, or CXCL13
 

 
/
 
 
 
mice
were resuspended in DMEM with 1% fetal bovine serum (FBS)
and labeled with 0.5 
 

 
M 5- and 6-carboxyfluorescein diacetate
succinimidyl ester (CFSE; Molecular Probes) for 10 min at 37
 

 
C,
washed once in DMEM with 10% FBS, and once in DMEM
with 1% FBS. After mixing with splenocytes from B6-Ly5
 
a 
 
mice
at a 1:1 ratio, cells were injected into the lateral tail vein of two
 

 
5-mo-old B6 or age-matched B6-
 
plt/plt
 
 mice (3 
 
 
 
10
 
7 
 
cells in
0.3 ml per mouse). BALB/c splenocytes were CFSE labeled and
transferred to BALB/c or BALB/c-
 
plt
 
/
 
plt
 
 recipients. Lymphoid
organ cells of recipient mice were harvested 90 min after transfer,
counted, and subject to flow cytometric analyses. For desensitiza-
tion experiments, spleen and lymph node cells from B6 mice
were labeled with CFSE as described above, and incubated with
PBS, 10 
 

 
g/ml mouse CCL19 (R&D Systems), 10 
 

 
g/ml hu-
man CXCL12 (Gryphon Laboratories), or combined CCL19
and CXCL12 (10 
 

 
g/ml each) for 45 min at 37
 

 
C. Cells were
transferred into 6-wk-old B6 mice (3 
 
 
 
10
 
7 
 
cells in 0.3 ml per
mouse), and lymphoid organ cells of recipient mice were har-
vested 20 min after transfer, counted, and subjected to flow cy-
tometric analyses. To normalize for the differences in the num-
ber of cells injected into each recipient, transfer data were
plotted as the number of cells of each type recovered in each re-
cipient per 10
 
6 
 
cells of the type intravenously transferred into the
recipient.
 
Flow Cytometry.
 
Lymphoid organ cells from recipient mice in
adoptive transfer experiments were stained for flow cytometry.
The following antibodies were used for surface staining: rat anti–
B220-Tricolor, rat anti–CD4-PE, rat anti–CD8a-PE (Caltag),
hamster anti–CD3e-biotin, rat anti–CD4-PerCP, rat anti–CD8a-
PerCP, and mouse anti–CD45.1 (Ly5
 
a
 
)-PE (BD PharMingen).
Hamster anti–CD3e-biotin was detected using streptavidin-allo-
phycocyanin (Molecular Probes). Stained cells were analyzed on
a FACSCaliber
 
® 
 
(Becton Dickinson).
 
Immunohistochemistry and In Situ Hybridization.
 
7–8-
 

 
m cryo-
stat sections of lymph nodes and Peyer’s patches of 6–10-wk-
old B6 mice were fixed in acetone and stained as previously de-
scribed (21) with the following antibodies: goat anti–CXCL12
(Santa Cruz Biotechnology, Inc.), goat anti–mouse CCL21, or
goat anti–mouse CXCL13 (R&D Systems); rat IgM anti–periph-
eral node addressin (PNAd) or rat anti–mucosal addressin cell ad-
hesion molecule (MAdCAM; BD PharMingen); and rat anti–
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B220-biotin (Caltag). Goat anti–CXCL12 antibody, after incuba-
tion with or without CXCL12 blocking peptide (62.5 
 

 
g/1 mg
antibody; Santa Cruz Biotechnology, Inc.) for 1 h on ice, was
centrifuged at 13,000 rpm for 1 min, and the supernatant was
used for staining. Goat antibodies were detected using biotinyl-
ated donkey anti–goat IgG antibody (Jackson ImmunoResearch
Laboratories) and Vectastain
 
®
 
 ABC-alkaline phosphatase (AP) kit
(Vector Laboratories). Rat IgM anti–PNAd antibody was de-
tected using horseradish peroxidase (HRP)-conjugated mouse
anti–rat IgM antibody (Southern Biotechnology Associates, Inc.).
Rat anti–MAdCAM antibody was detected using HRP-conju-
gated donkey anti–rat IgG antibody (Jackson ImmunoResearch
Laboratories). Rat anti–B220-biotin was detected using AP-con-
jugated streptavidin (Jackson ImmunoResearch Laboratories). AP
and HRP were detected as previously described (21). In situ hy-
bridization was performed as previously described (22, 25).
 
Intravital and Whole Mount Microscopy.
 
B6 mice with jugular
vein catheters were anesthetized by intraperitoneal injection of 10
ml/kg saline containing 1 mg/ml xylazine and 5 mg/ml ket-
amine. Superficial inguinal lymph nodes were prepared for intra-
vital microscopy as previously described (26). Mice were trans-
ferred to a fluorescence microscope (E800; Nikon) that was
equipped with an intensified CCD camera (ICCD-350F; Video
Scope International) connected to a Mini DV recorder (GV-
D900; Sony). Donor B cells were purified from the spleen and
lymph node cells of B6 mice by staining non–B cells with anti–
CD43-biotin (BD PharMingen), and depleted using streptavidin
MACS
 
®
 
 beads and a MACS
 
®
 
 (Miltenyi Biotec). Purity, as deter-
mined by B220 and CD3 staining, was 
 

 
95% B cells and T cell
contamination was 
 

 
0.5%. 3 
 
 
 
10
 
7
 
/ml purified B cells were la-
beled with 2 or 20 
 

 
M CFSE and incubated with PBS or com-
bined CCL19 and CXCL12 (10 
 

 
g/ml each) for 45 min at 37
 

 
C.
1.5 
 
 
 
10
 
7 
 
cells in 0.15 ml, which had been labeled with 2 
 

 
M
CFSE and incubated with PBS or chemokines, were injected into
mice via jugular vein catheters, and movements of transferred
cells in HEV branches (order II through IV venules according to
designations by von Andrian [26]) were recorded for 15 min after
injection. After turning down the camera gain so that the fluores-
cence of cells labeled with 2 
 

 
M CFSE was hardly detected,
1.5 
 
 
 
10
 
7
 
 cells in 0.15 ml, which had been labeled with 20 
 

 
M
CFSE and incubated with PBS or chemokines, were injected, and
cell movements in identical HEV branches were recorded for an-
other 15 min. From the recorded images, the numbers of freely
flowing cells, rolling cells, and cells arrested on vessels were
counted. For whole mount microscopy, purified B cells were la-
beled with either 20 
 

 
M CFSE or 20 
 

 
M tetramethylrhodamine-5-
and 6-isothiocyanate (TRITC; Molecular Probes, Inc.) using the
same procedure as previously described, and transferred to wild-
type recipients. After 20 min, Peyer’s patches were isolated,
placed in Fluoromount-G (Southern Biotechnology Associates,
Inc.), and examined by fluorescence microscopy.
 
Online Supplemental Material.
 
QuickTime™ videos showing
characteristic scenes from intravital microscopy experiments of
PBS-treated B cells and CCL19- plus CXCL12-desensitized
B cells. Online supplemental videos are available at http://www.
jem.org/cgi/content/full/jem.20020201/DC1.
 
Results
 
CXCR4 Functions in Lymphocyte Homing to Lymph Nodes
and Peyer’s Patches.
 
Although previous studies have not
identified a role for CXCR4/CXCL12 in B cell homing,
 
we considered the possibility that the function of this re-
ceptor–ligand pair in HEV attachment may have been
masked by partial redundancy with CCR7 and its ligands,
CCL19/CCL21. To test this possibility, we transferred
splenocytes from mice reconstituted with CXCR4
 

 
/
 
 
 
or
CXCR4
 

 
/
 
 
 
fetal liver cells to wild-type or CCL19- and
CCL21-deficient B6-
 
plt/plt
 
 mice. As shown in Fig. 1, the
accumulation of CFSE
 
 
 
CXCR4–deficient B cells in the
lymph nodes was dramatically suppressed in B6-
 
plt/
plt
 
 mice but not in wild-type mice, whereas CFSE
 

 
CXCR4
 

 
/
 
 
 
as well as Ly5
 
a
 
 
 
internal control B cells accu-
mulated in the lymph nodes of B6-
 
plt/plt
 
 mice as effi-
ciently as in wild-type mice. In Peyer’s patches, similar ob-
Figure 1. Defective homing of CXCR4-deficient B cells to lymph
nodes and Peyer’s patches of B6-plt/plt mice. (A) Representative flow cy-
tometric analysis of transferred B cell accumulation in mesenteric lymph
nodes of wild-type (wt) and B6-plt/plt recipients. CXCR4/ or
CXCR4/ splenocytes were CFSE labeled, mixed with wild-type con-
trol Ly5a splenocytes, and transferred into recipients for 90 min. Flow
cytometric analysis of cells from a wild-type recipient of CXCR4/ plus
Ly5a cells to show the separation of CFSE-labeled B and T cells, and the
B220-gate (top). B220-gated cells plotted against CFSE fluorescence and
Ly5a expression (bottom). Genotype of donor cell mixtures are indicated
above the plots and recipient genotypes are indicated on the right of the
plots. Gates demarcate the positions of CFSELy5a and CFSELy5a
cells, and the numbers next to boxes indicate the percentage of total
cells. (B) Enumeration of donor CXCR4/CFSELy5a B cells,
CXCR4/CFSELy5a B cells (shaded columns) and CFSELy5a in-
ternal control B cells (open columns) recovered from spleen, mesenteric
lymph nodes, inguinal and axillary lymph nodes, or four Peyer’s patches
of wild-type and B6-plt/plt recipients 90 min after transfer. Data are ex-
pressed as the number of CXCR4/, CXCR4/, or internal control B
cells recovered in each recipient per 106 respective B cells transferred.
Each symbol type represents an individual experiment. Columns show
means of these individual data points. The number of transferred
CXCR4/ cells in B6-plt/plt recipient mesenteric lymph nodes, inguinal
and axillary lymph nodes, and Peyer’s patches was significantly lower than
the number of CXCR4/ cells in wt recipients (P  0.01 in each case,
paired t test), and significantly lower than the number of CXCR4/ and
Ly5a wild-type cells in B6-plt/plt recipients (P  0.005 in each case,
Student’s t test). wt, wild type; MLN, mesenteric lymph nodes; PLN, in-
guinal and axillary lymph nodes; PP, Peyer’s patches.
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servations were obtained, although the suppression of B
cell homing by the blockade of these chemokine signals
was less pronounced than in lymph nodes (Fig. 1 B). The
effect of CXCR4 deficiency was selective to lymph nodes
and Peyer’s patches, as similar numbers of mutant and
wild-type cells were found in the spleen (Fig. 1 B) and
blood (unpublished data).
Consistent with earlier reports (15, 16, 18, 27), the
homing of wild-type T cells to lymph nodes and Peyer’s
patches was suppressed in B6-plt/plt mice (Fig. 2 A). Sig-
nificantly, the remaining accumulation of T cells that oc-
curred in the lymphoid organs of B6-plt/plt mice was al-
most completely abolished when the donor cells were
CXCR4 deficient (Fig. 2 A). In contrast, CXCR4-defi-
cient T cells accumulated normally in the lymphoid or-
gans of wild-type mice (Fig. 2 A). In the course of these
studies, it became evident that the suppression of T cell
homing in B6-plt/plt mice was less severe than in the prior
studies that had been performed in BALB/c- and DDD/
1-plt/plt mice (15, 16, 18), and a direct comparison of T
cell homing in B6- and BALB/c-plt/plt mice confirmed
that T cell homing was more severely compromised in
BALB/c-plt/plt mice (Fig. 2, A and B). The basis for this
difference is unclear but may reflect a higher expression of
the CCL21-leu gene in B6-plt/plt mice, or a greater trans-
port of CCL21-leu produced in lymphatic vessels to
lymph nodes. Consistent with the latter possibility, T cell
homing to Peyer’s patches, a tissue that does not receive
afferent lymph, was similarly affected in B6- and BALB/c-
plt/plt recipients (Fig. 2). Therefore, our observations es-
tablish that CXCR4 and CXCL12 can contribute to in
vivo T cell homing, but at the same time they indicate
that this pathway can, at most, support only a small
amount of the normal homing mediated by CCR7–
CCL19/CCL21.
Analysis of B cell homing in BALB/c-plt/plt mice re-
vealed a twofold suppression in homing to lymph nodes
and little suppression in homing to Peyer’s patches in 90-
min transfer experiments (unpublished data). In experi-
ments in which we transferred CCR7-deficient B cells to
B6 recipients, we observed a similar twofold inhibition in
B cell homing to lymph nodes (Fig. 3 A) consistent with
previous findings (17), and a lack of significant inhibition in
homing to Peyer’s patches (Fig. 3 A). The greater inhibi-
tion in lymph node homing in these experiments compared
with the observations in B6-plt/plt mice (Fig. 1) is consis-
tent with the interpretation that low amounts of CCL21
are present in B6-plt/plt lymph nodes. Importantly, how-
ever, the defect in CXCR4-deficient B cell homing in B6-
plt/plt mice (Fig. 1 B) was substantially greater then the de-
fect in CCR7-deficient B cell homing (Fig. 3 A).
As a further approach to test whether there was a com-
bined requirement for CXCR4 and CCR7 in B cell hom-
ing, and to exclude the possible effects caused by the
altered development of cells or lymphoid tissues in gene-
deficient animals, we tested the homing of chemokine-
desensitized wild-type lymphocytes in wild-type B6 mice. In
agreement with the transfer studies in B6-plt/plt mice, the
pretreatment of splenocytes with CCL19 and CXCL12
markedly suppressed B cell homing to lymph nodes,
whereas the pretreatment with either chemokine alone
caused only a small or no reduction of B cell homing abil-
ity (Fig. 3 B). Chemokine pretreatment did not have sig-
nificant effects on cell accumulation in the spleen (Fig. 3,
B and C), and treated and untreated cells were found in
similar frequencies in the blood (unpublished data). Typi-
Figure 2. CXCR4-dependent accumulation of T cells
in lymph nodes and Peyer’s patches of B6-plt/plt mice and
T cell homing in BALB/c-plt/plt mice. (A) Enumeration
of donor CXCR4/ or CXCR4/ CD4 and CD8 T
cells (shaded columns) and internal control CD4 and CD8
T cells (open columns) recovered from spleen, mesenteric
lymph nodes, inguinal and axillary lymph nodes, or four
Peyer’s patches of wild-type and B6-plt/plt recipients 90
min after transfer. CXCR4/ or CXCR4/ T cells were
identified as CD3CFSELy5a and internal control T
cells as CD3CFSELy5a. These data are from three of
the animals shown in Fig. 1. (B) Enumeration of do-
nor CFSECD4 or CFSECD8 BALB/c T cells in
BALB/c-plt/plt recipient tissues 90 min after transfer.
Each symbol type represents an individual experiment and
columns show means of these individual data points. The
number of transferred wild-type CD4 and CD8 T cells in
B6-plt/plt recipient mesenteric lymph nodes, inguinal and
axillary lymph nodes, and Peyer’s patches was significantly
lower than the number that reached these tissues in wild-
type recipients (P  0.01 in each case, paired t test). The
number of transferred CXCR4/ CD4 and CD8 cells in
B6-plt/plt recipient mesenteric lymph nodes, inguinal and
axillary lymph nodes, and Peyer’s patches was significantly
reduced compared with the number of CXCR4/ and
Ly5a wild-type cells reaching these organs in B6-plt/plt
recipients (P  0.03 in each case, Student’s t test). MLN,
mesenteric lymph nodes; PLN, inguinal and axillary lymph
nodes; PP, Peyer’s patches.
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cally, the desensitization method did not cause the same
extent of inhibition in lymph node and Peyer’s patch
homing as the genetic deficiencies, which most likely re-
flects the incomplete desensitization or resensitization of
some of the cells toward the end of the 20-min transfer
time. Also, in agreement with the genetic studies, the sup-
pression of B cell homing to Peyer’s patches by desensiti-
zation of CCR7 and CXCR4 was not as prominent as the
effect on B cell homing to lymph nodes (Fig. 3 B). As ex-
pected, T cell homing to lymph nodes and Peyer’s patches
was strongly diminished by pretreatment with CCL19
alone but not CXCL12 alone. Importantly, combined
CXCL12 and CCL19 treatment led to a significantly
greater inhibition in homing to peripheral lymph nodes
than CCL19 treatment alone (Fig. 3 C). A similar trend
was also observed for mesenteric lymph nodes and Peyer’s
patches, although in these cases the effect did not reach
statistical significance.
HEV-associated Localization of CXCL12 in Lymph Nodes
and Peyer’s Patches. The above results suggested that
CXCL12, as well as CCR7 ligands, was localized on
HEVs. To test this possibility, we performed in situ hy-
bridization and immunohistochemical analyses of CXCL12
expression. Strong CXCL12 mRNA expression was de-
tected in medullary cords as previously reported (22). In
addition, we observed CXCL12-expressing cells tightly as-
sociated with PNAd HEVs in both lymph nodes (Fig. 4,
A and B) and Peyer’s patches (Fig. 4, D and E). CXCL12-
expressing cells were sparse in other areas of the T zone
(Fig. 4, A–E) in contrast to the numerous CCL21-express-
ing T zone stromal cells (Fig. 4, C and F). We did not de-
tect CXCL12 expression by HEV cells (Fig. 4, B and E),
whereas CCL21 was expressed by these cells (Fig. 4, C and
F) as previously reported (7). Immunohistochemical stain-
ing of adjacent sections for CXCL12 and PNAd revealed
that CXCL12 protein is present on lymph node HEVs, in-
cluding the lumenal side of these vessels (Fig. 4, G and J).
The specificity of this staining was confirmed by the mark-
edly diminished staining intensity when the antiserum was
neutralized by preincubation with CXCL12 peptide (Fig.
4, I and L). A comparison of the pattern of staining by
PNAd and CXCL12 indicated that most PNAd vessels
were also positive for CXCL12 (Fig. 4, G–I and unpub-
lished data). Similar signals for CXCL12 were observed on
Peyer’s patch HEVs (unpublished data). B220 staining
showed the presence of B cells around CXCL12 HEVs
(Fig. 4, A, H, and K).
CXCR4 and CCR7 Are Involved in B Cell Attachment to
HEVs. To assess directly whether CXCL12 and CCL19/
CCL21 localized at HEVs triggers the arrest and firm adhe-
sion of B cells undergoing selectin-mediated rolling inter-
actions with the endothelium, we observed B cell behavior
in superficial inguinal lymph nodes by intravital micros-
copy. The low number of B cells generated in CXCR4-
deficient fetal liver chimeras precluded us from using this
genetic system for intravital studies. Instead, we used
chemokine-desensitized cells, an approach previously used
successfully to study chemokine requirements for T lym-
phocyte attachment to HEVs (15, 16). Because the ability
of HEVs to support lymphocyte rolling and firm adhesion
varies with the size of the vessel and possibly other parame-
ters, we injected chemokine-treated and PBS-treated B
cells, which had been loaded with 10-fold different con-
centrations of CFSE, one after the other into the same
mice and observed their behavior in the identical vessel
branches. As shown in Fig. 5, A–C, rolling fractions of
PBS-treated B cells and B cells treated with a combination
of CCL19 and CXCL12 were similar. Strikingly, the frac-
tion of chemokine-desensitized B cells that arrested and be-
came firmly adherent was 3.4-fold lower than that of con-
trol B cells (Fig. 5, A, B, and D). These observations
establish that the chemokine signals through CCR7 and
CXCR4 are involved in the mechanism that triggers B cell
arrest and firm adhesion to HEVs.
Figure 3. Suppression of B and T cell homing by desensitization of
CCR7 and CXCR4. (A) Enumeration of donor CCR7/CFSELy5a B
cells, CCR7/CFSELy5a B cells (shaded columns), and CFSELy5a
internal control B cells (open columns) recovered from spleen, mesenteric
lymph nodes, inguinal and axillary lymph nodes, or four Peyer’s patches
of wild-type recipients 90 min after transfer (mean 	 SD; n 
 7). The
number of CCR7/ B cells reaching mesenteric lymph nodes and in-
guinal and axillary lymph nodes was significantly reduced compared with
CCR7/ cells (P  0.05, paired t test). (B) Enumeration of donor
CFSE B cells and (C) donor CFSE T cells, which had been incubated
with PBS, 10 g/ml CCL19 (ELC), 10 g/ml CXCL12 (SDF1), or a
combination of CCL19 and CXCL12 (10 g/ml each) at 37C for 45
min before transfer, recovered from spleen, mesenteric lymph nodes, in-
guinal lymph nodes, or three Peyer’s patches (PP) of wild-type recipients
20 min after transfer. Each symbol type represents an individual experi-
ment and columns show means of these individual data points. The num-
ber of CCL19  CXCL12 pretreated B cells reaching mesenteric lymph
nodes and inguinal lymph nodes was significantly reduced compared with
PBS treated cells (P  0.05, paired t test), whereas the effect in Peyer’s
patches did not reach statistical significance (P 
 0.09). The number of
CCL19  CXCL12 pretreated T cells reaching inguinal and axillary
lymph nodes was significantly reduced compared with CCL19 pretreated
T cells (P  0.05), whereas the effect in mesenteric lymph nodes and
Peyer’s patches was not statistically significant (P 
 0.07 and 0.15, respec-
tively). MLN, mesenteric lymph nodes; PLN, inguinal and axillary lymph
nodes; PP, Peyer’s patches.
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CXCR5 and CXCL13 Contribute to the B Cell Homing
Mechanism in Peyer’s Patches. In contrast to the findings in
lymph nodes, transferred B cells accumulated in Peyer’s
patches to considerable numbers, even when both CCR7
and CXCR4 signaling was blocked (Figs. 1 and 3). These
findings suggested that additional chemokine signals were
involved in B cell entry to Peyer’s patches. As CXCL13 is
highly expressed in Peyer’s patches, and CXCL13 and
CXCR5 are important for normal development of Peyer’s
patches, it seemed possible that this chemokine–receptor
pair might be involved in B cell entry to this organ. By im-
munohistochemical analyses, CXCL13 was not detected at
HEVs near the edges or outside of follicles. However,
we found CXCL13 HEVs located inside follicles
where CXCL13 is abundantly expressed (Fig. 6 A). These
CXCL13 HEVs were MAdCAM and were typically
smaller than those in the T zones (Fig. 6 B). Previous stud-
ies have shown that a fraction of the B cells entering Peyer’s
patches migrate through small vessels located within folli-
cles (16, 28). Equivalently CXCL13-stained vessels were
not observed in lymph nodes (unpublished data).
To test whether CXCR5 played a role in B cell hom-
ing to Peyer’s patches, we transferred splenocytes from
CXCR5/ or wild-type mice with splenocytes from
Ly5a mice to wild-type recipients. As shown in Fig. 6 C,
the accumulation of CXCR5-deficient B cells in Peyer’s
patches in 90 min was significantly diminished, whereas the
homing to lymph nodes and spleen was hardly affected by
the CXCR5 deficiency of B cells. In control experiments,
the accumulation of B cells from CXCL13/ mice in
wild-type Peyer’s patches was similar to that of wild-type B
cells, establishing that the lack of Peyer’s patches in donor
mice was not the cause of the suppressed homing of
CXCR5-deficient B cells (Fig. 6 C, ). As expected, the
homing of CXCR5/ T cells to Peyer’s patches was indis-
tinguishable from wild-type controls (unpublished data).
To further test whether CXCR4, CXCR5, and CCR7
were the principal chemokine receptors involved in the B
Figure 4. Detection of CXCL12
(SDF1) on HEVs in lymphoid
organs. (A–F) In situ hybridiza-
tion analysis of CXCL12 and (C
and F) CCL21 (SLC) mRNA
expression (dark blue) in adja-
cent sections (A–C) of a mesen-
teric lymph node and (D–F) a
Peyer’s patch in combination
with immunohistochemical stain-
ing (brown) for (A and D) B220
and (B, C, E, and F) PNAd to
detect B cells and HEVs, respec-
tively. Green arrowheads in A,
B, D, and E indicate the posi-
tions of HEVs. Objective magni-
fication, 20. (G–L) Immunohis-
tochemical analysis of CXCL12
protein distribution in lymph
nodes. Adjacent sections of
mesenteric lymph node were
stained with anti-CXCL12 (G
and J, red), anti-B220 (H and K,
red), anti-PNAd (H and K,
brown), and anti-CXCL12 anti-
body preincubated with CXCL12
blocking peptide (I and L, red).
(J–L) High magnification images
of the boxed areas in G–I. f, folli-
cle; T, T zone. Objective magni-
fication: G–I, 5; J–L, 20.
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cell homing to Peyer’s patches, CXCR5-deficient cells
were pretreated with CCL19 and CXCL12, and transferred
to wild-type recipients for 20 min. Compared with wild-
type cells, in which 270 	 36 cells per 106 transferred cells
homed to Peyer’s patches in these very short-term experi-
ments, 44% fewer (150 	 4; n 
 3) CXCR5-deficient cells
and 63% fewer (100 	 7; n 
 3) CCL19  CXCL12 pre-
treated CXCR5–deficient cells accumulated in Peyer’s
patches during this time. The studies above (Figs. 1 and 3),
comparing the homing of CXCR4-deficient cells in B6-
plt/plt mice and of CCL19  CXCL12 pretreated wild-
type cells in wild-type mice, showed that the chemokine
pretreatment approach only caused a partial inhibition of
CCR7- and CXCR4-mediated homing. Taken together,
these findings favor the conclusion that CXCR5, CXCR4,
and CCR7 account for the majority of the chemokine re-
ceptor requirements for B cell homing to Peyer’s patches,
with CXCR5 playing a limited role, and CCR7 and
CXCR4 making redundant contributions.
The CXCL13-staining pattern (Fig. 6 A) suggested that
the CXCL13–CXCR5 ligand–receptor pair may be selec-
tively required for B cells to attach to HEVs within Peyer’s
patch follicles. To test this possibility, we cotransferred
TRITC-labeled wild-type and CFSE-labeled CXCR5-
deficient B cells into wild-type mice and examined their
distribution within Peyer’s patches 20 min later by whole
mount microscopy (Fig. 6, D–F). Consistent with previous
findings (16, 28), wild-type B cells were found to attach to
vessels within follicles in addition to the larger vessels in T
cell areas (Fig. 6, D–F, red cells). In contrast, CXCR5-defi-
cient B cells failed to accumulate in vessels within B cell fol-
licles, although they could be observed associated with ves-
sels in T cell areas (Fig. 6, D–F, green cells). These results
reveal a selective role for CXCL13 and CXCR5 in B cell
homing via follicle-associated HEVs into Peyer’s patches.
Discussion
The above results establish that CCR7 and CXCR4 are
the major chemokine receptors involved in B cell entry
into lymph nodes. In Peyer’s patches, an additional che-
mokine receptor, CXCR5, contributes nonredundantly to
B cell homing. CXCR4 is also able to support a low level
of T cell homing to lymph nodes and Peyer’s patches when
CCR7 ligands are deficient. Messenger RNA for the
CXCR4 ligand, CXCL12, was identified in cells adjacent
to HEVs, and CXCL12 protein was detectable on the lu-
menal surface of HEVs. CXCL13, the ligand for CXCR5,
was detected on a subset of Peyer’s patch but not lymph
node HEVs. Taken together, these studies define the
Figure 5. Combined desensi-
tization of CXCR4 and CCR7
prevents B cell arrest on lymph
node HEVs. (A) Representa-
tive time-lapse intravital micro-
graphs of superficial inguinal
lymph node HEVs, in which
transferred 2-M CFSE-labeled,
chemokine-desensitized B cells
flowed and rolled. Donor B cells
had been incubated with a
combination of CCL19 and
CXCL12 (10 g/ml each) be-
fore transfer. Transferred cells
appearing in the vessel branches
are numbered in their order of
appearance. The time elapsed,
starting from the first frame
shown, is indicated in each im-
age. B cells numbered 1–3 and 6
rolled on HEVs, but none of the
cells became arrested. (B) Re-
presentative time-lapse intravital
micrographs of the same superfi-
cial inguinal lymph node HEVs
as in A, after secondary injection
of 20-M CFSE-labeled B cells,
which had been incubated with
PBS. B cells numbered 1 and
3–5 rolled on HEVs, and 1 and 4
were arrested on HEVs until the
end of recording (5 min; see
Videos 1 and 2 available at http://
www.jem.org/cgi/content/full/
jem.20020201/DC1). (C and D) Fractions of B cells passing through HEVs that were recorded as (C) rolling or (D) arrested. B cells had been pretreated
with PBS or with combined CCL19 and CXCL12 as in A and B. Arrested B cells were defined as cells that were adherent for greater than 1 min. Open
symbols represent data from experiments in which chemokine-desensitized cells were injected first, and filled symbols represent data from experiments in
which PBS-treated cells were injected first. Columns show means of the individual datasets. The number of CXCL12  CCL19 pretreated cells that
stuck was significantly reduced (P 
 0.04, paired t test).
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chemokine code required for B cell trafficking into periph-
eral lymphoid organs (Fig. 7).
CCL21 was the first chemokine shown to be made by
HEVs, and it is present at high levels on the abluminal and
lumenal surface of HEVs as well as within T cell areas (7,
15, 16). Expression of CCL19, by contrast, has not been de-
tected in endothelial cells (25). However, CCL19 is ex-
pressed by T zone stromal cells surrounding HEVs (13, 25),
and CCL19 protein has been reported to be transcytosed by
endothelial cells and presented on the lumenal side of HEVs
(8). Earlier studies established that CXCL8 (IL-8) was effi-
ciently transcytosed and displayed by endothelial cells (29),
and more recently CCL2 (MCP1) and CXCL9 (MIG) have
been found to be transcytosed and displayed by HEVs (30,
31). In this study, we show that CXCL12, like CCL19, is
not detectably expressed by HEVs, but is expressed by cells
adjacent to HEVs and is displayed on the HEV lumen. The
nature of the CXCL12-expressing cell type is presently un-
clear, although it is interesting that in human skin CXCL12
has been identified in the pericytes that surround endothelial
cells (32). Although not previously reported on HEVs,
CXCL12 has been observed on skin endothelial cells (32),
bone marrow endothelial cells (33), and endothelium within
the rheumatoid synovium (34). Additional studies are
needed to determine the mechanism by which CXCL12 is
transcytosed and displayed by endothelial cells. In the case of
CXCL13 HEVs in Peyer’s patches, it is currently unclear
whether the follicular HEVs express CXCL13 mRNA.
However, large amounts of CXCL13 are made by stromal
cells throughout the follicle and it seems likely that at least a
fraction of the chemokine displayed by the follicular HEVs
is derived from the surrounding stromal cells. Recently,
CXCL13 HEVs were identified in human tonsil (35), a B
cell–rich mucosal lymphoid tissue that has similar features to
Peyer’s patches, which indicates that the display of CXCL13
by follicular HEVs in such tissues is a conserved property
between mice and humans. Peyer’s patches and tonsils are
chronically activated and usually contain many germinal
centers. It will be interesting to determine whether antigen-
induced responses promote transcytosis and display of
CXCL13 on follicle-associated HEVs.
Our experiments show that when the chemokine signals
through both CCR7 and CXCR4 are reduced or blocked,
B cell accumulation in the lymph nodes is decreased 90%
compared with wild-type levels (Fig. 1). This extent of in-
hibition approached that observed for B cells treated with
pertussis toxin, in which the number of treated cells recov-
ered from lymph nodes was reduced by 95% in short-
term transfer experiments (unpublished data). Therefore,
CCR7 and CXCR4 are responsible for the majority of Gi-
coupled signaling required for B cell homing to lymph
nodes during homeostasis. Our findings and previous stud-
ies (17) indicate that when B cells are deficient only in
CCR7 they have a partial reduction in lymph node hom-
ing, whereas CXCR4 deficiency alone did not cause a
measurable loss of homing ability. Similar conclusions were
suggested by our findings with chemokine-desensitized
wild-type cells, in which CCL19 desensitization caused a
small decrease in homing to wild-type lymph nodes,
whereas CXCL12 desensitization alone did not affect hom-
Figure 6. Involvement of CXCL13
(BLC) and CXCR5 in B cell homing to
Peyer’s patches. (A and B) Immunohis-
tochemical analysis of CXCL13 distribution
in Peyer’s patches. Adjacent Peyer’s patch
sections were stained for (A) CXCL13
(blue), or B220 (red), and (B) MAdCAM
(brown). A CXCL13 HEV is indicated by
the arrow, and higher magnification images
of this vessel are shown in the insets. e, epi-
thelium; f, follicle; T, T zone. Objective
magnification, 10 (insets, 40). (C) Enu-
meration of donor CXCR5/	CFSE B
cells, CXCR5/CFSE B cells (shaded
columns) and CFSELy5a internal control
B cells (open columns) recovered from
spleen, mesenteric lymph nodes, inguinal
and axillary lymph nodes, or four Peyer’s
patches of wild-type recipients 90 min after
transfer. In the transfer experiment shown
by the filled squares, the CXCR5/ donor
was CXCL13/. The number of trans-
ferred CXCR5/ cells in Peyer’s patches
was significantly lower than the number of
CXCR5/ cells (P  0.001, paired t test).
Similar findings were obtained in a separate
experiment using CXCL13/ recipients. MLN, mesenteric lymph nodes; PLN, inguinal and axillary lymph nodes; PP, Peyer’s patches. (D–F) Whole
mount microscopy of Peyer’s patches from mice that had received CFSE-labeled CXCR5/ and TRITC-labeled wild-type B cells 20 min earlier. Images
in D and E are of the same field at different focal planes to provide detail of cells in the (D) T zone versus the (E) follicle. F shows a view of a vessel within
another Peyer’s patch. Objective magnification, 20. The location of follicles and T cell areas was determined by orientating the Peyer’s patch under low
magnification (5) and comparing the image with images obtained from similarly orientated Peyer’s patches from animals that had received fluorescently
labeled T cells. The data in D–F are representative of vessels observed in more than 10 Peyer’s patches in three experiments. f, follicle; T, T cell.
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ing. Therefore, the role of CCR7 in B cell entry to lymph
nodes and Peyer’s patches appears to be partially redundant
with CXCR4, whereas the contribution of CXCR4 ap-
pears to be fully redundant with CCR7.
In contrast to lymph nodes, Peyer’s patch homing was
only 50% affected by the combined blockade of CCR7
and CXCR4. However, when B cells were selectively defi-
cient in CXCR5, there was also about a twofold decrease in
Peyer’s patch homing (Fig. 6). CXCR5-deficient cells that
had been pretreated with CCL19 and CXCL12 showed a
more complete (63%) block in homing. We consider that
our inability to fully block Peyer’s patch homing by this ap-
proach was due to the incomplete inhibition achieved by
chemokine pretreatment, but at the present time we cannot
exclude a small contribution to Peyer’s patch homing by an
additional chemokine. Decreased Peyer’s patch homing was
not reported in earlier studies of CXCR5 and CXCL13 de-
ficient mice, most likely because animals with endogenous
deficiencies in these genes have severe defects in early steps
of Peyer’s patch development and have few, if any, Peyer’s
patches (20, 21). In other studies, it was observed that B
cells preferentially attach to HEVs within Peyer’s patch fol-
licles, at the borders of follicles, and at T cell areas, whereas
T cells enter preferentially via HEVs in T cell areas (16, 28).
CCL21 was found to be selectively expressed by HEVs in T
cell areas and follicle-associated HEVs showed minimal
CCL21 expression (16). Taking these observations together
with our finding that CXCL13 HEVs are limited to folli-
cles, and that the CXCR5 contribution to B cell Peyer’s
patch homing was nonredundant, it appeared likely that
CXCR5 and CXCL13 would play a limiting role in B cell
attachment to follicle-associated HEVs. This was confirmed
by whole mount microscopy analysis, in which CXCR5-
deficient B cells were found to be inefficient in attachment
to follicle-associated HEVs. Therefore, we propose that the
CXCR5–CXCL13 receptor–ligand pair plays a selective
role in B cell trafficking across HEVs within Peyer’s patch
follicles (Fig. 7).
In agreement with other studies (36, 37), we observed
differences in the relative efficiency of B and T cell entry to
Peyer’s patches compared with lymph nodes. Although T
cells home to lymph nodes and Peyer’s patches more effi-
ciently than B cells, the difference in efficiency was 5–10-
fold for lymph nodes but less than twofold for Peyer’s
patches (compare Figs. 1 and 2). The greater relative effi-
ciency of B cell homing to Peyer’s patches compared with
lymph nodes was mostly lost when the cells lacked
CXCR5 (Fig. 6). Therefore, we conclude that differences
in the HEV chemokine code contribute to differences in
the efficiency of B and T lymphocyte homing to different
lymphoid organs. These differences, along with differences
in B and T cell retention time within the tissue (37), may
contribute to the greater predominance of B than T cells in
Peyer’s patches.
Our results show that CXCR4 is able to function in T
cell homing to lymph nodes and Peyer’s patches. However,
as established in past studies (17, 18), CCR7 and its ligands
play a dominant role in T cell homing (Fig. 7), and the
contribution of CXCR4 appears to be fully redundant
with CCR7. The difference in the chemokine dependence
of T and B cells for homing may reflect the differential re-
sponsiveness to CCL19/CCL21 with relatively similar re-
sponsiveness to CXCL12. T cells express 10-fold higher
surface levels of CCR7 than B cells (unpublished data) and
they are substantially more responsive to the respective
ligands in in vitro chemotaxis assays (7, 25). Both CCL19
and CCL21 have been shown to promote T and B lym-
phocyte adhesion to intercellular adhesion molecule 1
(ICAM1; references 9 and 10) and MAdCAM1 (38).
CXCL12 has been shown to promote adhesion of periph-
eral blood lymphocytes to ICAM1 (9, 10), although direct
tests of purified B cells have not been reported. It will be
interesting to determine whether T cells are more sensitive
than B cells in their CCL19 and CCL21 concentration re-
quirements for triggering integrin-mediated adhesion to
ICAM1 and MAdCAM1.
As already noted, a well-established feature of lympho-
cyte homing is that T cells enter lymph nodes with consid-
erably greater efficiency than B cells (compare Figs. 1 and
2; references 36 and 37). One mechanism contributing to
this difference appears to be the higher expression of L-selec-
tin on T cells compared with B cells (37). We propose that
another mechanism is the greater responsiveness of T cells
to CCL19/CCL21 than B cells coupled with the high con-
centration of CCL21 on lymph node HEVs. Consistent
with the chemokine triggering step contributing to the dif-
fering efficiency of T and B cell homing, the fraction of
rolling B cells that underwent arrest in lymph node HEVs
Figure 7. Principal chemokine requirements for B and T cell entry
into lymph nodes and Peyer’s patches. The diagram represents a lymph
node or Peyer’s patch T zone HEV on the left and a Peyer’s patch follic-
ular HEV on the right. CCL21 (SLC) is expressed by endothelial cells
(oval shaped), whereas CXCL12 (SDF1) is expressed by stromal cells (tri-
angular shaped) juxtaposed to HEVs. Both chemokines are presented on
the lumenal side of HEVs. CCL19 (ELC) expressed by T zone stromal
cells may also be presented on these HEVs (not shown). Large amounts of
chemokine are also present in an abluminal location (not shown). CCR7
plays an indispensable role in triggering T cell adhesion, and CXCR4 can
contribute partially to this process. B cells are triggered to adhere by ei-
ther CCR7 or CXCR4, with CCR7 supporting approximately twofold
more adhesion triggering events than CXCR4. Follicular areas of Peyer’s
patches contain HEVs of a smaller diameter than the T zone HEVs, and
these vessels display CXCL13 (BLC), most likely derived from follicular
stromal cells, although CXCL13 may also be expressed by the endothelial
cells. B cells are triggered to adhere to these vessels by CXCL13/
CXCR5. CXCR5 supports 50% of the chemokine triggering require-
ment for B cell homing to Peyer’s patches. Most T cells do not express
CXCR5 and are not triggered to adhere to HEVs in follicles, passing
through to T zone HEVs where they may be arrested. T, T cells; B, B cells.
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(Fig. 5 and supplemental Quicktime videos available at
http://www.jem.org/cgi/content/full/jem.20020201/DC1)
was lower than that observed for T cells (6, 15).
An additional implication of our findings is that T cells
that have modulated CCR7 expression may be able to
continue entering lymph nodes and Peyer’s patches via the
CXCR4 pathway. Although memory T cells often modu-
late CXCR4 (39, 40), some memory cells maintain expres-
sion (41). A fraction of circulating memory T cells also ex-
press CXCR5 (42, 43). Other circulating cell types that are
CCR7-low or -negative and that express CXCR4 or
CXCR5, such as monocytes and immature dendritic cells
(40, 44), may also be able to use these receptors for trigger-
ing adhesion to endothelium.
In summary, CCR7 and CXCR4 are the major recep-
tors providing the triggering signals for B cell entry into
lymph nodes, and CXCR5 as well as CXCR4 and CCR7
provide the triggering signals for B cell entry into Peyer’s
patches (Fig. 7). The presence of large amounts of the
ligands for each of these receptors on the abluminal side of
HEVs, in addition to the lumenal side, suggests that they
may function both in triggering firm adhesion of rolling
cells and in the subsequent diapedesis step. Although a che-
mokine gradient may not be critical for diapedesis, a Gi-
coupled receptor signal is needed (45). In addition to their
expression in secondary lymphoid tissues, CXCL12 is ex-
pressed in bone marrow and in epithelial tissues, and both
CXCL12 and CXCL13 have been identified at sites of
chronic inflammation (33, 46). Our findings support a role
for CXCL12 in promoting adhesion and transmigration of
circulating stem and plasma cells across bone marrow endo-
thelium, and in the entry of B cells and CXCR4 memory
T cells to sites of inflammation (34, 41).
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